LLY vs TCRT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and TCRT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and TCRT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Alaunos Therapeutics, formerly Ziopharm Oncology, spent years as a clinical-stage cancer cell-therapy company developing T-cell receptor (TCR-T) therapies for solid tumors. In 2023 it wound down its sole clinical study and cut most of its workforce, prioritizing its hunTR neoantigen-TCR discovery platform and exploring strategic alternatives. By 2026 the company had pivoted again, repositioning itself as a preclinical obesity and metabolic-disorders company centered on ALN1003, an oral small-molecule candidate that it describes as a non-hormonal, non-incretin approach (different from GLP-1 drugs). It has reported early preclinical, animal-model data suggesting weight and metabolic effects, but the program is pre-human, so there is no clinical proof of safety or efficacy in people, and no product revenue.

Full TCRT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• TCRT drivers: Obesity and metabolic pivot (ALN1003); Non-hormonal, non-incretin differentiation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For TCRT, the risks here are severe and existential, and outweigh the typical risks of a normal stock.

Pick LLY if you believe its drivers more; TCRT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and TCRT guides.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

TCRT. All figures are approximate and tied to the asOf date; verify live numbers before acting, because a company in this condition can change rapidly through dilution, a reverse split, a financing, or delisting. Traditional valuation is not meaningful here: with no revenue, near-zero cash, and going-concern and delisting risk, the stock is priced on survival odds and speculation, not on earnings or assets. A very low share price does not make it cheap.

Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); TCRT shows revenue trend No product revenue; the company is preclinical with its lead obesity candidate. Any income is incidental, not from product sales., profitability Deeply unprofitable, as expected for a preclinical biotech; ongoing net losses and cash burn with no near-term path to earnings., balance sheet About $0.35 million in cash as of March 31, 2026, with runway estimated only into Q2 2026 and going-concern risk. Verify the latest cash position, which can change quickly., nasdaq listing status Received an April 2026 deficiency notice for failing the $2.5 million minimum stockholders' equity rule; at risk of delisting pending a remediation plan..

LLY and TCRT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and TCRT exposure against your real portfolio. It is not an investment adviser.